Department of Oral and Cranio-Maxillo-Facial Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
Oral Oncol. 2009 Nov;45(11):963-7. doi: 10.1016/j.oraloncology.2009.06.008. Epub 2009 Aug 8.
Patients with oral squamous cell carcinoma (OSCC) and poor prognosis may benefit from an intensification of the initial therapy scheme. To improve the clinical management of these patients, there is a strong requirement for an accurate assessment of the malignant properties of the individual lesion. The objective of the present analysis was to define the potential value of 2-[(18)F]fluoro-2-deoxy-d-glucose ((18)FDG) uptake in the tumor measured by positron emission tomography (PET) in predicting patients' outcome in the clinical course of OSCC. In this respect, a clinically well-defined cohort of 79 patients with primary OSCC was retrospectively evaluated. (18)FDG uptake in the primary tumor site was quantified by calculation of the maximum standardized uptake values (SUV(max)). Subsequent statistical analyses found, that (18)FDG uptake of the primary tumor was significantly higher in stage T3/T4 vs. T1/T2 (p<0.001), in UICC stage IV vs. stage I-III (p=0.01), and in N1-3 vs. N0 tumors (p<0.001), respectively. To define SUV(max) cut-off values for survival analyses, receiver operating curves (ROC) were calculated for overall and disease-free survival after 36 and 60 months, respectively. Univariate survival analysis showed that high SUV(max) was significantly associated with shortened overall survival after 36 (p=0.026) and 60 months (p=0.02). Subsequent multi-variate Cox regression analysis including SUV(max), age, gender and UICC stage as co-variables determined that, high SUV(max) was the only predictor of inferior overall survival after 60 months (p=0.035) in this model. In conclusion, (18)FDG uptake detected by PET predicts adverse outcome of patients with OSCC in this retrospective analysis. (18)FDG-PET might be a promising tool to contribute to therapeutic decisions and should be evaluated in future prospective studies.
口腔鳞状细胞癌(OSCC)患者预后较差,可能受益于初始治疗方案的强化。为了改善这些患者的临床管理,强烈需要准确评估个体病变的恶性程度。本分析的目的是定义正电子发射断层扫描(PET)测量的肿瘤中 2-[(18)F]氟-2-脱氧-d-葡萄糖((18)FDG)摄取在预测 OSCC 临床病程中患者预后方面的潜在价值。在这方面,回顾性评估了一组临床明确的 79 例原发性 OSCC 患者。通过计算最大标准化摄取值(SUV(max))来量化原发性肿瘤部位的 (18)FDG 摄取。随后的统计分析发现,T3/T4 期与 T1/T2 期(p<0.001)、UICC 分期 IV 期与 I-III 期(p=0.01)、N1-3 期与 N0 期肿瘤(p<0.001)相比,原发性肿瘤的 (18)FDG 摄取明显更高。为了定义 SUV(max)用于生存分析的截断值,分别计算了 36 个月和 60 个月时总生存率和无病生存率的受试者工作特征曲线(ROC)。单因素生存分析显示,高 SUV(max)与 36 个月(p=0.026)和 60 个月(p=0.02)总生存率缩短显著相关。随后的多变量 Cox 回归分析包括 SUV(max)、年龄、性别和 UICC 分期作为协变量,确定高 SUV(max)是该模型中 60 个月时总体生存率较差的唯一预测因素(p=0.035)。总之,在这项回顾性分析中,PET 检测到的 (18)FDG 摄取预测了 OSCC 患者的不良预后。(18)FDG-PET 可能是一种有前途的工具,可以帮助做出治疗决策,应在未来的前瞻性研究中进行评估。